Skip to content
ChickenStockChickenStock
ResearchRXRX
Recursion Pharmaceuticals logo

Recursion Pharmaceuticals (RXRX) stock

NASDAQ

$3.19-4.35%(-0.14)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-4.16x

Net loss — not comparable

P/B

2.19x

P/S

28.75x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 280.0% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 2, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

14 SEC filings
  • Borgeson BlakeDirector · Nov 3, 2026Open-market sale40,000 shares · $155K
    Avg. price $3.886,068,287 shares held after
  • Hassan FredDirector · Nov 2, 2026Grant or award156,658 shares · $0
    Avg. price $0156,658 shares held after
  • Borgeson BlakeDirector · Oct 6, 2026Open-market sale50,000 shares · $242K
    Avg. price $4.846,108,287 shares held after
  • HERSHBERG ROBERTDirector · Oct 6, 2026Open-market sale25,000 shares · $125K
    Avg. price $5162,156 shares held after
  • HERSHBERG ROBERTDirector · Oct 6, 2026Option exercise25,000 shares · $56K
    Avg. price $2.22187,156 shares held after
  • Dar ZavainDirector · Oct 1, 2026Grant or award4,607 shares · $0
    Avg. price $0245,371 shares held after
  • Li Dean YDirector · Oct 1, 2026Grant or award3,378 shares · $0
    Avg. price $01,476,707 shares held after
  • Taylor Ben RChief Financial Officer · Sep 15, 2026Shares withheld for taxes5,396 shares · $18K
    Avg. price $3.411,071,462 shares held after
  • Khan NajatCEO and President · Sep 8, 2026Open-market sale22,408 shares · $79K
    Avg. price $3.51762,072,890 shares held after
  • Borgeson BlakeDirector · Sep 1, 2026Open-market sale30,000 shares · $100K
    Avg. price $3.346,158,287 shares held after
  • Khan NajatCEO and President · Aug 17, 2026Shares withheld for taxes80,498 shares · $254K
    Avg. price $3.162,095,298 shares held after
  • Hallett DavidChief Scientific Officer · Aug 17, 2026Shares withheld for taxes26,657 shares · $84K
    Avg. price $3.161,043,837 shares held after
  • Taylor Ben RChief Financial Officer · Aug 17, 2026Shares withheld for taxes25,018 shares · $79K
    Avg. price $3.161,076,858 shares held after
  • Borgeson BlakeDirector · Aug 4, 2026Open-market sale30,000 shares · $98K
    Avg. price $3.256,188,287 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Recursion Pharmaceuticals (RXRX) stock information

NASDAQ

Recursion Pharmaceuticals (RXRX) is listed on NASDAQ. Its market capitalization is about $2B. On trailing-twelve-month earnings the P/E ratio is -4.16, and the P/B ratio is 2.19. Return on equity is -52.6%. These figures are computed in-house from official filings and are reference information only.

Recursion Pharmaceuticals — frequently asked questions

What is the P/E ratio of Recursion Pharmaceuticals (RXRX)?
On a trailing-twelve-month basis, RXRX trades at a P/E ratio of -4.16. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Recursion Pharmaceuticals?
RXRX has a market capitalization of about $2B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.